Bausch Health Companies Inc. BHC
8.18 USD +0.22 (+2.76%)
At closeNov 9, 2026, 7:00 AM EST
8.25 +0.07 +0.86%
Pre-market · Nov 9, 7:00 AM ET
7.88 Day range 8.20
4.33 52-week range 9.04
- YTD
- +17.70%
- 1 year
- +22.27%
News
benzinga.com Bausch Health And Gastroenterology Unit Salix Pharmaceuticals To Present New Data On Cirrhosis Trends And Severe Alcohol-Associated Hepatitis At The Liver Meeting, November 5–9 To present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and
prnewswire.com Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the…
zacks.com BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks Bausch Health Companies Inc. BHC emphasized sustained operational growth, stronger cash generation and improved financial flexibility during its third-quarter 2026 earnings call. Management raised…
zacks.com Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year? Here is how Bausch Health (BHC) and Bausch + Lomb (BLCO) have performed compared to their sector so far this year.
benzinga.com Jefferies Maintains Hold on Bausch Health Companies, Raises Price Target to $8 Jefferies analyst Young Li maintains Bausch Health Companies (NYSE:BHC) with a Hold and raises the price target from $6.5 to $8.
benzinga.com RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $10 RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perform and raises the price target from $9 to $10.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc…
benzinga.com Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
benzinga.com Bausch Health Companies Q3 2026 Earnings Call Transcript Bausch Health Companies (NYSE:BHC) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market session. Glaukos (NYSE:GKOS) stock rose 16.85% to $212.01. The company's market cap stands at $10.6…
benzinga.com Bausch Health Companies Announces $50M Buyback Plan Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase its common shares…- benzinga.com Bausch Health Companies Raises FY2026 Sales Guidance from $10.790B-$11.040B to $10.975B-$11.175B vs $10.927B Est Bausch Health Companies (NYSE:BHC) raises FY2026 sales outlook from $10.790 billion-$11.040 billion to $10.975 billion-$11.175 billion vs $10.927 billion estimate.
benzinga.com Bausch Health Companies Q3 Adj. EPS $1.77 Beats $1.29 Estimate, Sales $2.941B Beat $2.757B Estimate Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $1.77 per share which beat the analyst consensus estimate of $1.29 by 37.21 percent. This is a 52.59 percent increase over earnings…- benzinga.com Bausch Health Canada Announces Expanded Public Reimbursement For PrOKEDI 75 Mg And 100 Mg, With Coverage Now Available In Seven Provinces And Multiple Federal Drug Plans PrOKEDI® is now listed in Ontario, Quebec, British Columbia, Alberta, Saskatchewan, Nova Scotia and Prince Edward Island, as well as through federal drug plans administered by the Non-Insured Health…
benzinga.com Why Is Bausch + Lomb Stock Falling Monday? Bausch + Lomb stock drops 10% following sudden CEO departure, despite raising full-year 2026 EBITDA guidance.- benzinga.com Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D Preliminary Update on 2026 Guidance2Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1…
benzinga.com Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
benzinga.com This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold Paulson's hedge fund reduced its equity book to $2.58B in Q2, exiting two positions and opening a stake in Alphabet.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Nuwellis (NASDAQ:NUWE) stock moved upwards by 123.7% to $4.23 during Thursday's regular session. GlucoTrack (NASDAQ:GCTK) shares moved upwards by 79.85% to $0.51. The company's market cap…
benzinga.com Bausch Health Companies Raises FY2026 Sales Guidance from $10.670B-$10.920B to $10.790B-$11.040B vs $10.773B Est Bausch Health Companies (TSX:BHC) raises FY2026 sales outlook from $10.670 billion-$10.920 billion to $10.790 billion-$11.040 billion vs $10.773 billion estimate.- benzinga.com Bausch Health Companies Q2 Adj. EPS $1.26 Beats $1.06 Estimate, Sales $2.852B Beat $2.679B Estimate Bausch Health Companies (TSX:BHC) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.06 by 17.76 percent. This is a 38.46 percent increase over earnings of…
- benzinga.com Bausch Health Announces Quebec Provincial Listing Of Prokedi For Treatment Of Schizophrenia In Adults PrOKEDI® is a prolonged-release injectable suspension of risperidone indicated for the treatment of schizophrenia in adults. According to the Canadian product monograph, PrOKEDI® achieves clinically…
- benzinga.com Bausch Health, Canada, Completes Negotiations With pan-Canadian Pharmaceutical Alliance Resulting In LOI For PrOKEDI 75mg And 100mg, Long-Acting Injectable Antipsychotic Agent For Schizophrenia Treatment Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance…
- benzinga.com Bausch Health And Solta Medical Announce Thermage Awarded AAA Well-Known Trademark Certification By China Trademark Association Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May…
benzinga.com Bausch Health Companies Raises FY2026 Sales Guidance from $10.625B-$10.875B to $10.670B-$10.920B vs $10.595B Est Bausch Health Companies (NYSE:BHC) raises FY2026 sales outlook from $10.625 billion-$10.875 billion to $10.670 billion-$10.920 billion vs $10.595 billion estimate.- benzinga.com Bausch Health Companies Q1 Adj. EPS $0.78 Beats $0.69 Estimate, Sales $2.524B Beat $2.409B Estimate Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.69 by 13.04 percent. This is a 27.87 percent increase over earnings…
benzinga.com Earnings Scheduled For April 29, 2026 - benzinga.com RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $9 RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perform and lowers the price target from $10 to $9.
benzinga.com Barclays Maintains Equal-Weight on Bausch Health Companies, Lowers Price Target to $7 Barclays analyst Glen Santangelo maintains Bausch Health Companies (NYSE:BHC) with a Equal-Weight and lowers the price target from $8 to $7.- benzinga.com Bausch Health Companies Sees FY2026 Sales $10.625B-$10.875B vs $10.595B Est Bausch Health Companies (NYSE:BHC) sees FY2026 sales of $10.625 billion-$10.875 billion vs $10.595 billion analyst estimate.
benzinga.com Insights into Bausch Health Companies Q4 Earnings 
benzinga.com Bausch Health Companies Q4 Earnings Report: What Investors Need to Know - benzinga.com Bausch Health Companies Q4 Adj. EPS $1.10 Misses $1.26 Estimate, Sales $2.796B Beat $2.696B Estimate Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $1.10 per share which missed the analyst consensus estimate of $1.26 by 12.97 percent. This is a 5.98 percent decrease over earnings…
- benzinga.com Earnings Scheduled For February 18, 2026
- benzinga.com Attorney General James Secures More Than $17M from Drug Manufacturers Bausch And Lannett For Conspiracy To Inflate Prices https://ag.ny.gov/press-release/2026/attorney-general-james-secures-more-17-million-drug-manufacturers-bausch-and
- benzinga.com Bausch Health Reports Results Of Global Phase 3 RED-C Clinical Program; Trials Safe, But Did Not Meet Primary Endpoint Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin solid soluble dispersion (SSD) in adults with…
- benzinga.com Truist Securities Maintains Hold on Bausch Health Companies, Raises Price Target to $8 Truist Securities analyst Les Sulewski maintains Bausch Health Companies (NYSE:BHC) with a Hold and raises the price target from $7 to $8.
- benzinga.com Looking Into Bausch Health Companies Inc's Recent Short Interest
- benzinga.com Barclays Initiates Coverage On Bausch Health Companies with Equal-Weight Rating, Announces Price Target of $8 Barclays analyst Glen Santangelo initiates coverage on Bausch Health Companies (NYSE:BHC) with a Equal-Weight rating and announces Price Target of $8.
benzinga.com Leggett & Platt, New Fortress Energy, Bausch Health Companies And Other Big Stocks Moving Higher On Monday - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Bausch Health Companies And Its Global Aesthetic Business, Solta Medical, Acquired Wuhan Shibo Zhenmei Technology, Consisting Of The Shibo Group's Aesthetics Distribution Business, Deal Terms Were Not Disclosed The Shibo group has served as Solta Medical's trusted distribution partner over the past decade. Effective December 1, 2025, Wuhan Shibo Zhenmei Technology Co., Ltd. became a wholly owned subsidiary…
benzinga.com Carl Icahn's Biggest Bet Just Torched Half His Fortune Carl Icahn's empire, IEP, has collapsed 80% due to Hindenburg's short-selling attack. Icahn's net worth is down 75%.
benzinga.com Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday - benzinga.com Bausch Health Companies Q3 Adj. EPS $1.16 Beats $1.13 Estimate, Sales $2.681B Beat $2.637B Estimate Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.13 by 2.38 percent. This is a 3.57 percent increase over earnings of…
- benzinga.com Bausch Health Companies Raises FY2025 Sales Guidance from $10.000B-$10.250B to $10.050B-$10.250B vs $10.141B Est Bausch Health Companies (NYSE:BHC) raises FY2025 sales outlook from $10.000 billion-$10.250 billion to $10.050 billion-$10.250 billion vs $10.141 billion estimate.
benzinga.com Earnings Scheduled For October 29, 2025 
benzinga.com Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites.
benzinga.com Bausch Health's Triple-Combination Acne Gel CABTREO Now Covered By Quebec And Saskatchewan Drug Plans Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that PrCABTREO™ (clindamycin phosphate, adapalene…- benzinga.com A Look Into Bausch Health Companies Inc's Price Over Earnings